AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 NOV 6 - (NewsRx.com & NewsRx.net) -- The impact on a patient's reproductive health is often a misunderstood part of treating their underlying medical condition.
Gathering at the annual meeting of the American Society for Reproductive Medicine, held October 11-15, 2003, physicians discussed new developments in helping those patients with the reproductive consequences of their conditions.
A prospective comparison of tamoxifen alone and tamoxifen-FSH combined protocol for IVF & fertility preservation in breast cancer patients. Researchers at Weill Medical College of Cornell University revealed the results of using tamoxifen or tamoxifen with follicle stimulating hormone (FSH) added to increase the chances of success when breast cancer survivors undergo assisted reproduction for either fertility preservation or treatment of infertility.
Because the chemotherapy for their cancer often leaves them infertile, patients need assisted reproductive technologies (ART) to cryopreserve their embryos in order to have children in the future. This treatment is also used for cancer survivors who are infertile after chemotherapy and need ART to conceive. However, many of the drugs used to stimulate egg production may be dangerous to cancer patients.
This study found that using the tamoxifen-FSH combination was a safe alternative to unstimulated cycles and resulted in a greater number of embryos than tamoxifen alone.
Fertility preservation using ART and embryo cryopreservation prior to chemotherapy in breast cancer patients: New and safe protocol for ovarian stimulation. Doctors in Ramat Gan, Israel, are working on ways to make ovarian stimulation safer for breast cancer patients who want to preserve fertility by undergoing ...
Source: HighBeam Research, New advances reported in treating reproductive consequences of other...